Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Shrinking investment and a lack of innovation in the development of new antibiotics is "undermining efforts to combat drug-resistant infections," the World Health Organization warned on Friday, citing two of its new reports.

Why it matters: "Without government intervention, the United Nations estimates that resistant infections could kill 10 million people annually by 2050 and prompt an economic slowdown to rival the global financial crisis of 2008," the New York Times reports.

What's happening: It can take up to 10 years and north of $2 billion to develop a new antibiotic and commercialize it, the Times writes. Large pharmaceutical companies aren't producing as many antibiotics, and of those that are being developed, only a handful target the most dangerous drug-resistant infections.

  • Drug company executives, public health experts and patient advocates are insisting that Washington establish new programs and policies to attract the necessary funding to help struggling antibiotic companies and continue to attract drug company giants.
“Never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent. Numerous initiatives are underway to reduce resistance, but we also need countries and the pharmaceutical industry to step up and contribute with sustainable funding and innovative new medicines.”
WHO's Director-General, Tedros Adhanom Ghebreyesus

Between the lines: "Unlike drugs that treat chronic conditions and are taken for years, antibiotics save lives, but are taken for just a week or two, diminishing their profitability for drugmakers," the NYT's Andrew Jacobs writes.

The other side: In WHO's report on possible novel therapies, 252 agents in development were identified to target 12 pathogens declared serious threats to humanity, including E. coli, salmonella and the bacteria that can cause gonorrhea.

Yes, but: Among 50 new antibiotics in clinical trials, only two are active against the most worrisome category of bugs, per the Times.

Go deeper: U.S. pushes global effort to fight antibiotic resistance at UN meeting

Go deeper

Shell and GM unveil partnership on Texas power and car-charging

Illustration: Annelise Capossela/Axios

General Motors and a Shell-owned power company will unveil a partnership on Wednesday aimed at providing renewable electricity to Texas customers and free overnight charging to state residents who own GM electric cars.

Why it matters: It’s a new way for two corporate giants to expand their operations in a way that lowers emissions at the customer and supplier level.

Mike Allen, author of AM
44 mins ago - Politics & Policy

First look: WaPo Trump book's secret title revealed

Cover: Penguin Press

The Washington Post's Carol Leonnig and Philip Rucker will be out July 20 with "I Alone Can Fix It: Donald J. Trump’s Catastrophic Final Year," Penguin Press announced.

Why it matters: With the swelter of Trump books that begins this summer, authors have been keeping their publishing plans secret. This publishing date puts Leonnig and Rucker a week ahead of the juggernaut Michael Wolff, whose "Landslide" is scheduled for July 27.

The Democrats' wake-up call

Eric Adams, a former cop who leads the New York mayoral race, speaks last night at the Schimanski nightclub in Williamsburg, Brooklyn. Photo: Robert Nickelsberg/Getty Images

Democrats, in private and public, are warning that rising crime — and the old and new progressive calls to defund the police — represent the single biggest threat to their electoral chances in 2022.

Why it matters: There has been a big spike in big-city crime, a dynamic increasingly captured in local coverage and nationally on CNN and Fox News.